Founded in 1998 by the renowned immunologist Bernard Mach, University of Geneva.

Privately held company with focus on discovering and developing primarily fully human antibody-based drugs to fight autoimmune & inflammatory diseases and cancer.

Headquarter in Plan-les-Ouates, Geneva and in December 2016 opening of Branch Office in Basel.

Since its inception, the company successfully created 16 mono- and bi-specific human antibodies.

The company has grown from 0 to 160 employees (22 nationalities), highly skilled in discovery, preclinical research & manufacturing and clinical research between 1999 and 2019.

In 2019 NovImmune has successfully divested EmaCo AG a newly established company owning emapalumab (the anti-IFNγ monoclonal antibody, Gamifant®) and related assets to SOBI.

NovImmune SA continues to operate and focus on its bi-specific technology and associated programs and has rebranded as “Light Chain Bioscience – A brand of Novimmune SA”.

Novimmune preclinical bi-specific Ab programs sold to Light Chain Bioscience AG, Geneva.

  • Nominated in 2020